Body surface area‐based vs concentration‐based perioperative intraperitoneal chemotherapy after optimal cytoreductive surgery in colorectal peritoneal surface malignancy treatment: COBOX trial

2019 ◽  
Vol 119 (7) ◽  
pp. 999-1010 ◽  
Author(s):  
Lieselotte Lemoine ◽  
Elsy Thijssen ◽  
Robert Carleer ◽  
Karlien Geboers ◽  
Paul Sugarbaker ◽  
...  
Keyword(s):  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Peritoneal Surface Malignancy ◽  
Peritoneal Surface

scholarly journals Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization

Oncotarget ◽  
2019 ◽  
Vol 10 (14) ◽  
pp. 1407-1424 ◽  
Author(s):  
Lieselotte Lemoine ◽  
Elsy Thijssen ◽  
Robert Carleer ◽  
Jirka Cops ◽  
Veerle Lemmens ◽  
...  
Keyword(s):  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Rat Model ◽  
Peritoneal Surface Malignancy ◽  
Perioperative Chemotherapy ◽  
Peritoneal Surface ◽  
Versus Concentration

scholarly journals Body Surface Area Predicts Plasma Oxaliplatin and Pharmacokinetic Advantage in Hyperthermic Intraoperative Intraperitoneal Chemotherapy

2013 ◽  
Vol 20 (4) ◽  
pp. 1101-1104 ◽  
Author(s):  
Joshua C. Leinwand ◽  
Gleneara E. Bates ◽  
John D. Allendorf ◽  
John A. Chabot ◽  
Sharyn N. Lewin ◽  
...  
Keyword(s):  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Intraperitoneal Chemotherapy

scholarly journals Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2471
Author(s):  
Philipp Horvath ◽  
Can Yurttas ◽  
Stefan Beckert ◽  
Alfred Königsrainer ◽  
Ingmar Königsrainer
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
University Hospital ◽  
Peritoneal Surface Malignancy ◽  
Treatment Protocols ◽  
Primary Tumors ◽  
Peritoneal Surface ◽  
Group 2 ◽  
Group 1

(1) Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provide survival benefits to selected patients. We aimed to report our experience and the evolution of our peritoneal surface malignancy program. (2) Methods: From June 2005 to June 2017, 399 patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at the Tübingen University Hospital were analyzed from a prospectively collected database. (3) Results: Peritoneal metastasis from colorectal cancer was the leading indication (group 1: 28%; group 2: 32%). The median PCI was 15.5 (range, 1–39) in group 1 and 11 (range, 1–39) in group 2 (p = 0.002). Regarding the completeness of cytoreduction (CC), a score of 0 was achieved in 63% vs. 69% for group 1 and 2, respectively (p = 0.010). Median overall survival rates for patients in group 1 and 2 for colon cancer, ovarian cancer, gastric cancer and appendix cancer were 34 and 25 months; 45 months and not reached; 30 and 16 months; 39 months and not reached, respectively. The occurrence of grade-III and -IV complications slightly differed between groups (14.5% vs. 15.6%). No 30-day mortality occurred. (4) Conclusions: Specialized centers are able to provide low-morbidity cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without mortality. Strict patient selection during the time period significantly improved CC scores.

scholarly journals The PEritoneal SUrface CAlculator (PESUCA): A new tool to quantify the resected peritoneal surface area after cytoreductive surgery

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Philipp Schredl ◽  
Jan Philipp Ramspott ◽  
Daniel Neureiter ◽  
Klaus Emmanuel ◽  
Tarkan Jäger
Keyword(s):  
Surface Area ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Relative Proportion ◽  
External Validation ◽  
The Body ◽  
Programming Algorithm ◽  
Peritoneal Disease ◽  
Disease Extent ◽  
Peritoneal Surface

AbstractBackgroundThe body surface area (BSA) is taken as a measure for the effective contact area for dosing in hyperthermic intraperitoneal chemotherapy (HIPEC). Currently, the pharmacokinetic effect of the reduced peritoneal surface area (PSA) after cytoreductive surgery (CRS) during HIPEC remains unclear. Here a proprietary software solution (PEritoneal SUrface CAlculator (PESUCA)) to quantify the resected PSA in patients with peritoneal surface malignancies (PSM) undergoing CRS and HIPEC is presented.MethodsThe PESUCA tool was programmed as a desktop and online software solution. The applicability was evaluated in 36 patients. The programming-algorithm is briefly summarized as follows: (1) calculation of BSA, (2) correlation to PSA, (3) calculation of the relative proportion of 40 different anatomical regions to total PSA before CRS, (4) instantaneous input of each resected proportion in the 40 anatomical regions during CRS, and (5) determination of the resected and remaining PSA after CRS.ResultsThe proof of concept revealed a mean PSA of all patients before CRS of 18,741 ± 321 cm2 compared to 13,611 ± 485 cm2 after CRS (p<0.0001). Patients’ supramesocolic and inframesocolic visceral and parietal peritoneal area before and after CRS procedure were quantitatively determined.ConclusionsHere the first tool that enables detailed PSA quantification in patients with PSM undergoing CRS is presented. This makes the software a valuable contribution to ensue more accurate assessment and improved comparability of peritoneal disease extent. Furthermore, after external validation, PESUCA could be the basis for dose adjustment of intraperitoneal chemotherapy regimens based on the remaining PSA after CRS.

scholarly journals Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist's perspective

2016 ◽  
Vol 23 (4) ◽  
pp. 233-238 ◽  
Author(s):  
Priya Mistry ◽  
Faheez Mohamed ◽  
Sanjeev Dayal ◽  
Tom D Cecil ◽  
Brendan J Moran
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Peritoneal Surface Malignancy ◽  
Peritoneal Surface
Sign in / Sign up

Export Citation Format

Share Document